These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22552292)

  • 1. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
    Xu L; Kikuchi E; Xu C; Ebi H; Ercan D; Cheng KA; Padera R; Engelman JA; Jänne PA; Shapiro GI; Shimamura T; Wong KK
    Cancer Res; 2012 Jul; 72(13):3302-11. PubMed ID: 22552292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
    Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
    Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
    Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
    Shimamura T; Li D; Ji H; Haringsma HJ; Liniker E; Borgman CL; Lowell AM; Minami Y; McNamara K; Perera SA; Zaghlul S; Thomas RK; Greulich H; Kobayashi S; Chirieac LR; Padera RF; Kubo S; Takahashi M; Tenen DG; Meyerson M; Wong KK; Shapiro GI
    Cancer Res; 2008 Jul; 68(14):5827-38. PubMed ID: 18632637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
    Ortiz-Zapater E; Lee RW; Owen W; Weitsman G; Fruhwirth G; Dunn RG; Neat MJ; McCaughan F; Parker P; Ng T; Santis G
    PLoS One; 2017; 12(1):e0170798. PubMed ID: 28141869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
    Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Katayama T; Tomizawa K; Osada H; Sekido Y; Maehara Y; Yatabe Y; Mitsudomi T
    Clin Cancer Res; 2010 Nov; 16(22):5489-98. PubMed ID: 21062933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW; Chen TC; Huang HS; Lee H
    Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.